Oxaluria evolution.
PreclinicalSmall molecule
Oxaluria evolution. is one of 6 small molecule programs targeting Primary Hyperoxaluria Type 1. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Primary Hyperoxaluria Type 1
#DrugCompanyPhaseTrials
1Diacomit
BBiocodex
Phase 3
Oxlumo
Alnylam PharmaceuticalsPhase 2
DCR-PHXC
DDicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 2
ABO-101
AArbor Biotechnologies
Phase 2
Rivfloza
Novo NordiskPreclinical
Oxaluria evolution.
HHospices Civils de Lyon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxaluria evolution.. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHospices Civils de Lyon